Ingredients
Each mL contains:
0.4 mg/mL non-viable propionibacterium acnes suspended in 12.5% ethanol in saline.

Dosage and Administration
EqStim must be administered by the intravenous (IV) route.
Shake well to obtain uniform suspension
Foals: ...................................... 1 mL
Older Horses: .......................... 1 mL per 250 lbs of body weight
Repeat dosages at day three (or day four) and at day seven, and weekly thereafter as needed.

Caution
May be a rise in temperature, tremors, temporary loss of appetite, or sluggishness a few hours after injection.
Anaphylactoid reactions may occur. In the event of anaphylactoid reaction administer epinephrine.

Warning
The effects of this immunostimulant have not been studied on pregnant animals. Do not use when pregnancy is known or suspected.
For animal use only.
Keep out of reach of children.
Not for human use.

Storage
Store at a temperature between 15°-30° C (56°-86° F) until first used.
Refrigerate after opening.
Do not freeze.
EqStim®
Immunostimulant

Why use EqStim?

EqStim has been demonstrated to be effective in increasing the rate of recovery when used in conjunction with antibiotic or hyperimmune therapy in the treatment of primary and secondary bacterial and viral infections associated with equine respiratory disease complex.

- Proven to provide rapid recovery from bacterial and viral respiratory infections
- Employs no adjuvants - safe for adult horses, ponies, and foals
- Evaluated in mares diagnosed with persistent endometritis. Results of this randomized, double-blinded clinical trial were published in the July 1, 2007 issue of JAVMA¹
- Made in the U.S.A.

¹ Contact Neogen for a complimentary reprint of this article:

Rohrbach, Barton W., VMD, MPH, DACVPM; Peter C. Sheerin, DVM, DACT; Charles K. Cantrell, DVM; Phillip M. Matthews, DVM; John V. Steiner, DVM, DACT; Lewis E. Dodds, DVM. “Effect of adjunctive treatment with intravenously administered Propionibacterium acnes on reproductive performance in mares with persistent endometritis.” JAVMA July 1, 2007; 231(1): 107-113